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Cardiomyocytes Bind and Activate Native Human Prorenin
Role of Soluble Mannose 6-Phosphate Receptors
Jasper J. Saris, Frans H.M. Derkx, Jos M.J. Lamers, Pramod R. Saxena,
Maarten A.D.H. Schalekamp, A.H. Jan Danser
Abstract—Cardiomyocytes bind, internalize, and activate recombinant human prorenin through mannose 6-phosphate/
insulin-like growth factor II (M6P/IGFII) receptors. To investigate whether this also applies to native human prorenin,
neonatal rat myocytes were incubated for 4 hours at 37°C with various prorenin-containing human body fluids. Uptake
and activation by M6P/IGFII receptors were observed for plasma prorenin from subjects with renal artery stenosis and/or
hypertension and for follicular fluid prorenin. The total amount of cellular renin and prorenin (expressed as percentage
of the levels of renin and prorenin in the medium) after 4 hours of incubation was 4 to 10 times lower than after
incubation with recombinant human prorenin. Although plasma contains alkaline phosphatases capable of inactivating
the M6P label as well as soluble M6P/IGFII receptors that block prorenin binding in a competitive manner and proteins
(eg, insulin, IGFII) that increase the number of cell-surface M6P/IGFII receptors, these factors were not responsible for
the modest uptake of native human prorenin. Uptake did not occur during incubation of myocytes with plasma prorenin
from anephric subjects or with amniotic fluid prorenin, and this was not due to the presence of excessively high levels
of M6P/IGFII receptors and/or phosphatase activity in these fluids. In conclusion, myocytes are capable of binding,
internalizing, and activating native human prorenin of renal and ovarian origin through M6P/IGFII receptors.
Differences in prorenin glycosylation and/or phosphorylation as well as the concentration of soluble M6P/IGFII
receptors and growth factors affecting cell-surface M6P/IGFII receptor density determine the amount of prorenin
entering the heart and thus cardiac angiotensin II production. (Hypertension. 2001;37[part 2]:710-715.)
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The beneficial effects of ACE inhibitors on postinfarctremodeling and in subjects with heart failure are gener-
ally attributed to interference with cardiac angiotensin (Ang)
II production.1 Initially, it was thought that the renin required
for cardiac Ang II generation is synthesized de novo in the
heart. However, it is now well established that cardiac renin
is largely if not completely derived from the circulation, both
under normal and pathological conditions.2–5 Circulating
renin and/or its inactive precursor, prorenin, diffuse into the
cardiac interstitial space5,6 or bind to (pro)renin receptors.7,8
We recently reported that one of these receptors is identical to
the mannose 6-phosphate/insulin-like growth factor II (M6P/
IGFII) receptor.9,10 M6P/IGFII receptors not only have bind-
ing domains for M6P-containing ligands such as renin and
prorenin but also for IGFII and retinoic acid.11,12 Interest-
ingly, prorenin binding to M6P/IGFII receptors is followed
by rapid internalization and activation.9,10 This is not a unique
property because it also applies to other M6P-containing
prohormones (eg, latent transforming growth factor-b).13
In our studies on M6P/IGFII receptor–mediated prorenin bind-
ing, we made use of recombinant human prorenin. This prorenin
may differ from native human renal prorenin with regard to its
glycosylation and/or phosphorylation.14–16 Similar differences exist
between prorenin of renal and extrarenal origin.16,17 In fact, the
absence of the M6P label on extrarenal prorenin could explain why
Ang II is virtually undetectable in the heart after a bilateral
nephrectomy2,18 despite the fact that prorenin, unlike renin, is still
present in circulating blood of nephrectomized subjects, sometimes
at levels as high as those in normal individuals.19–21
In this study, we set out to investigate whether cardiomyocytes
bind, internalize, and activate native human prorenin of renal and
extrarenal origin through M6P/IGFII receptors, taking into consid-
eration the fact that plasma and other prorenin-containing human
body fluids (eg, amniotic fluid) contain factors that may interfere
with prorenin binding, such as soluble M6P/IGFII receptors, phos-
phatases, and proteins that increase the number of cell-surface
M6P/IGFII receptors (eg, insulin and IGFII).11,22
Methods
Cell Culture
All experiments were performed according to the regulations of the
Animal Care Committee of Erasmus University Rotterdam (The
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Netherlands), in accordance with the “Guiding Principles in the Care
and Use of Laboratory Animals” as approved by the Council of the
American Physiological Society.
Primary cultures of rat neonatal cardiac cells were prepared as
described before.9 Briefly, ventricles of newborn 1- to 3-day-old
Wistar strain rat pups were minced, and cells were dispersed by
trypsinization. Myocytes were separated from nonmyocytes by
differential preplating and seeded in noncoated 12-well plates
(Corning Costar), giving a confluent monolayer of spontaneously
beating cells at 1.53105 cells/cm2 after 24 hours. Cells were
maintained at 37°C in a humidified 5% CO2 incubator in 1.5 mL
medium consisting of DMEM and Medium 199 (4:1) (Gibco Life
Technologies) and supplemented with 100 U penicillin/mL (Roche),
100 mg streptomycin/mL (Roche), 5% fetal calf serum (Roche), and
5% horse serum (Sigma). Before the start of each experiment, cells
were washed 3 times with 1 mL warm (37°C) PBS (consisting of
140 mmol/L NaCl, 2.6 mmol/L KCl, 1.4 mmol/L KH2PO4, and
8.1 mmol/L Na2HPO4, pH 7.4). They were then preincubated at 4°C
or 37°C for 30 minutes with 0.4 mL medium supplemented with 1%
(wt/vol) BSA (Sigma).
At 4°C, prorenin binds to cell-surface receptors without being
internalized, whereas at 37°C, prorenin binding M6P/IGFII receptors
is followed by internalization and intracellular activation to renin.9,10
Moreover, at the latter temperature, M6P/IGFII receptors continu-
ously recycle between the cell surface and intracellular
compartments.11
Binding and Activation of Native Prorenin
To study binding and activation of native human prorenin, cells were
incubated at 37°C with 0.4 mL incubation medium containing 30%
(vol/vol) blood plasma, amniotic fluid, or follicular fluid. Plasma
was obtained from 3 subjects with renal artery stenosis (1 man, 2
women; age, 41 to 66 years), 3 subjects with essential hypertension
treated with the ACE inhibitor captopril (2 men, 1 woman; age, 51
to 67 years), and 4 anephric subjects (1 man, 3 women; age, 33 to 61
years) who had been anephric for 1 to 11 years. Amniotic fluid was
obtained from 3 women (age, 19 to 38 years) after natural delivery.
Follicular fluid was obtained from 3 women (age, 30 to 39) during an
in vitro fertilization program. All incubations lasted 4 hours and were
performed with and without 10 mmol/L M6P to determine M6P/
IGFII receptor–specific binding. For comparison, incubations were
also performed with recombinant human prorenin (a kind gift of Dr
S. Mathews, Hoffmann-LaRoche) diluted in incubation medium to a
concentration comparable to the lowest concentration in the native
prorenin samples. At the end of the incubation period, the medium
was removed. Each well was washed 3 times with 1 mL ice-cold
PBS. Cells were then lysed in 0.2 mL ice-cold PBS containing 0.2%
Triton X-100 (Merck), and the cell lysates were quickly frozen on
dry ice. Media and cell lysates were stored at 270°C.
Recombinant Prorenin Binding and Internalization
in the Presence of Plasma or Amniotic Fluid
To study whether the soluble M6P/IGFII receptors and growth
factors that are present in plasma and amniotic fluid affect prorenin
binding and internalization by myocytes, cells were incubated at 4°C
or 37°C with 0.4 mL incubation medium containing 100 mU/mL
recombinant human prorenin in the presence of 0%, 1%, 3%, 10%,
or 30% (vol/vol) plasma (obtained from 6 healthy men; age, 26 to 64
years) or amniotic fluid (obtained from 3 women, see above). On the
basis of the levels of endogenous renin plus prorenin in plasma and
amniotic fluid (240 and 5200 mU/mL, respectively), it can be
estimated that the addition of plasma or amniotic fluid to medium
containing 100 mU/mL recombinant human prorenin marginally
(,2%) affected the levels of immunoreactive total renin. For
comparison, incubations were also performed with plasma that had
been incubated at 56°C for 1 hour to denature soluble M6P/IGFII
receptors. Incubations lasted 4 hours, and media and cell lysates were
collected and stored as described above.
Effect of Preincubation of Myocytes With Plasma
on Recombinant Prorenin Binding
To study whether incubation with plasma affects the number of
cell-surface M6P/IGFII receptors, cells were preincubated at 37°C
for maximally 2 hours with 0%, 3%, or 30% (vol/vol) plasma
(obtained from 6 healthy men, see above) or plasma that had been
incubated at 56°C for 1 hour. The cells were then washed 3 times
with 1 mL ice-cold PBS and incubated at 4°C for 4 hours with 100
mU/mL recombinant human prorenin. Thereafter, media and cell
lysates were collected and stored as described above.
Effect of Preincubation of Recombinant Prorenin
With Plasma or Amniotic Fluid
To study whether plasma or amniotic fluid contains phosphatase
activity toward the M6P label, 1 U recombinant human prorenin was
incubated for 24 hours at 4°C or 37°C in 1 mL 100 mmol/L HEPES
buffer (pH 7.4, Sigma), 0.5 mL HEPES buffer10.5 mL plasma
(obtained from 6 healthy men, see above), or 0.5 mL HEPES
buffer10.5 mL amniotic fluid (obtained from 3 women, see above)
in the presence or absence of the phosphatase-inhibitors imidazole
(25 mmol/L, final concentration) (Sigma), Na b-glycerophosphate
(5 mmol/L) (Sigma), and Na o-vanadate (2 mmol/L) (BDH Chem-
icals). Next, the pretreated recombinant human prorenin (diluted in
incubation medium to a final concentration of 100 mU/mL) was
incubated with myocytes for 4 hours at 4°C. Media and cell lysates
were collected and stored as described above.
Renin and Prorenin Measurements
In the experiments with recombinant human prorenin, cell-activated
prorenin (ie, renin) and total prorenin (ie, cell-activated plus nonac-
tivated prorenin) were measured by immunoradiometric assay, as
described before.10,23 The results of this assay are expressed as
milliunits per million cells or per milliliter of medium, with recom-
binant human prorenin used as a reference. The lower limit of
detection was 5 mU per million cells or per milliliter of medium. The
immunoradiometric assay is not sensitive enough to allow the
detection of the cellular renin and prorenin levels in the experiments
with plasma, amniotic fluid, and follicular fluid. The renin and
prorenin measurements in these experiments were therefore per-
formed by enzyme-kinetic assay.9 The results of this assay are
expressed as milliunits per million cells or per milliliter of medium,
with plasmin-activated recombinant human prorenin used as a
reference. The lower limit of detection was 1 mU per million cells or
per milliliter of medium.
Statistical Analysis
Results are expressed as mean6SEM. Data were compared by
means of a Student’s t test for paired observations or ANOVA. A
value of P,0.05 was considered to be significant.
Results
Binding and Activation of Native Prorenin
All samples of human origin (plasma, amniotic fluid, and
follicular fluid) contained predominantly prorenin. As a
result, the level of prorenin (expressed as a percentage of the
sum of renin and prorenin) in the media containing these
samples was $80% (Figure 1, top).
Incubation at 37°C with plasma from subjects with renal
artery stenosis or plasma from hypertensive subjects treated
with captopril, as well as incubation with follicular fluid,
resulted in uptake of renin and prorenin by myocytes (Figure
1, bottom). The uptake of plasma and follicular (pro)renin
was M6P/IGFII receptor mediated; it was abolished when
M6P was added to the medium. However, the amount of
(pro)renin present in the cells after 4 hours of incubation with
plasma or follicular fluid, expressed as a percentage of the
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renin and prorenin levels in the medium, was 4 to 10 times
lower than after incubation of the cells with recombinant
human prorenin (Figure 1).
At the end of the incubation period, the cells contained
predominantly (.75%) renin, indicating that the internalized
prorenin had been activated.
Incubation with plasma from nephrectomized subjects, or
with amniotic fluid, did not result in M6P/IGFII receptor–
mediated accumulation of renin or prorenin, despite the fact
that the prorenin levels in the medium containing these
samples were comparable to or much higher than the levels of
recombinant human prorenin that did result in cellular accu-
mulation of prorenin (Figure 1).
Recombinant Prorenin Binding and Internalization
in the Presence of Plasma or Amniotic Fluid
Plasma from healthy men as well as amniotic fluid inhibited
recombinant human prorenin binding at 4°C in a
concentration-dependent manner (Figure 2, left). Heat inac-
tivation, which denatures soluble M6P/IGFII receptors, abol-
ished this effect. Similar data were obtained with plasma from
anephric subjects (n53, data not shown). Remarkably, at
37°C, heat-inactivated plasma from healthy men enhanced
recombinant human prorenin uptake in a concentration-
dependent manner (Figure 2, right). This effect was not
observed during incubation with noninactivated plasma at
37°C. Activation of recombinant human prorenin by myo-
cytes (after 4 hours of incubation at 37°C, 8565% of total
cell-associated prorenin was activated, n56) was not affected
by coincubation with noninactivated or heat-inactivated
plasma (data not shown).
Effect of Preincubation of Myocytes With Plasma
on Recombinant Prorenin Binding
A 30-minute preincubation of myocytes with plasma of
healthy men increased recombinant human prorenin binding
by ’100% (Figure 3, left). This effect was diminished on
longer preincubation with plasma and occurred in a
concentration-dependent manner (Figure 3, right). Preincuba-
tion with heat-inactivated plasma yielded similar results.
Effect of Preincubation of Recombinant Prorenin
With Plasma or Amniotic Fluid
Preincubation of recombinant human prorenin with plasma or
amniotic fluid, with or without phosphatase inhibitors, did not
affect its binding to myocytes (Figure 4).
Discussion
This study shows that neonatal rat cardiomyocytes bind
native human prorenin through M6P/IGFII receptors. Binding
is limited to prorenin of renal and follicular origin and is
Figure 1. Binding and activation of native and recombinant
human prorenin by myocytes. Top, Renin (black bars) and pro-
renin (white bars) levels in medium. Bottom, Levels of cell-
associated renin (black bars) and prorenin (white bars) after 4
hours of incubation at 37°C in presence or absence of
10 mmol/L M6P. rhPR indicates recombinant human prorenin;
RAS, plasma from subjects with renal artery stenosis; CAP,
plasma from hypertensive subjects treated with captopril; Nx,
plasma from nephrectomized subjects; AF, amniotic fluid; and
FF, follicular fluid. Data are mean6SEM of 4 experiments.
*P,0.05 vs without M6P.
Figure 2. Cellular prorenin levels after incubation of myocytes
for 4 hours with 100 mU/mL recombinant human prorenin in
presence of noninactivated plasma (F), heat-inactivated plasma
(C), or amniotic fluid (n) at 4°C (left) or 37°C (right). Levels
(mean6SEM; n56 to 8) are expressed as percentage of levels
measured in absence of plasma or amniotic fluid. *P,0.05 vs
100%.
712 Hypertension February 2001 Part II
followed at 37°C by internalization and activation to renin.
Preincubation of myocytes with plasma at 37°C increases the
number of cell-surface M6P/IGFII receptors, thereby enhanc-
ing subsequent prorenin binding, whereas coincubation with
soluble M6P/IGFII receptors containing human body fluids
reduces prorenin binding to myocytes.
In previous studies, we demonstrated that myocytes bind
M6P-containing recombinant human renin and prorenin ex-
clusively through M6P/IGFII receptors.24 No evidence was
obtained for the presence of other (pro)renin receptors on
myocytes. Our current data, showing M6P/IGFII receptor-
mediated binding and activation of plasma prorenin, support
the concept of circulating, kidney-derived prorenin contrib-
uting to cardiac Ang II production. Our inability to demon-
strate uptake of circulating prorenin of anephric subjects
suggests that extrarenally produced prorenin lacks the M6P
signal. This might explain why cardiac tissue levels of Ang II
in anephric animals are close to or below the detection
limit,2,18 despite the continuous presence of prorenin in the
circulation of anephrics.19–21 Glycosylation differences be-
tween prorenin of renal and extrarenal origin are in full
agreement with the isoelectric heterogeneity of prorenin in
human body fluids.16,17,25
However, not all extrarenal prorenin lacks the M6P signal;
we did observe M6P/IGFII receptor–mediated binding and
activation of ovary-derived prorenin. Ovarian prorenin is
produced and secreted by the mature follicle and by the
corpus luteum26 and is largely responsible for the rise in
plasma prorenin that normally occurs during pregnancy.26,27
The function of ovarian prorenin in plasma is currently
unknown. On the basis of our data, it appears that ovarian
prorenin may participate in cardiac and vascular Ang II
production. Chorionic prorenin, in contrast with ovarian
prorenin, does not enter the circulation in significant
amounts,27 nor did we observe M6P/IGFII receptor–mediated
uptake of this prorenin by myocytes. The latter is not due to
the presence of phosphatase activity in amniotic fluid (Figure
4). Moreover, in agreement with our findings, the isoelectric
focusing profile of chorionic prorenin is different from that of
renal prorenin.17
All prorenin-containing human body fluid samples that
were applied in the present study also contained small
amounts of renin (,20% of total renin). After 4 hours of
incubation at 37°C with plasma or ovarian prorenin, the
myocytes, however, were found to contain predominantly
(.75%) renin. Because M6P/IGFII receptors do not make a
distinction between M6P-containing renin or prorenin,9,10 the
high cellular levels of renin cannot be explained on the basis
of selective uptake of renin. A more likely explanation is
therefore that native human prorenin, like recombinant hu-
man prorenin, is proteolytically activated after its binding to
M6P/IGFII receptors. Such activation occurs intracellularly,
as demonstrated previously with the acid-wash method.10
M6P/IGFII receptors recycle between the cell surface and
intracellular compartments, and the majority of the cellular
M6P/IGFII receptors is located intracellularly.11 Because of
this continuous recycling, the cellular prorenin levels are
higher after incubation at 37°C than after incubation at 4°C
and increase proportionally with the levels of prorenin in the
medium.24 In the present study, the cellular levels of native
renin1prorenin (expressed as a percentage of the
renin1prorenin levels in the medium), measured after 4 hours
of incubation at 37°C with plasma, were several times lower
than after incubation with recombinant human prorenin. This
may have several reasons. First, the percentage of plasma
(pro)renin molecules containing the M6P signal may be lower
than the percentage of recombinant human prorenin mole-
cules (’40%)24 carrying this signal. If so, this is not due to
phosphatase activity in plasma (Figure 4).
Second, plasma contains high levels (’3.5 nmol/L)22 of
soluble M6P/IGFII receptors, which, through competition,
will prevent M6P-containing prorenin from binding to cellu-
lar M6P/IGFII receptors. Under the conditions of our incu-
bation experiments (0.6 million cells exposed to 0.4 mL
medium containing 30% plasma), the number of soluble
receptors in the medium will exceed the number of cell-
surface receptors (’4000/cell)24 by a factor of 100. Indeed, in
agreement with the presence of soluble M6P/IGFII receptors,
Figure 3. Cellular prorenin levels after incubation of myocytes
for 4 hours with 100 mU/mL recombinant human prorenin after
preincubation of cells with 30% plasma for 0.5, 1, or 2 hours
(left) or with 3% or 30% noninactivated (F) or heat-inactivated
(C) plasma for 2 hours (right). Levels (mean6SEM; n56) are
expressed as percentage of levels measured without preincuba-
tion of cells.
Figure 4. Cellular prorenin levels after incubation of myocytes
for 4 hours at 4°C with 100 mU/mL recombinant human prore-
nin after preincubation of recombinant human prorenin for 24
hours at 4°C or 37°C with HEPES buffer, plasma, or amniotic
fluid in presence or absence of phosphatase inhibitors. Levels
(mean6SEM; n53 to 6) are expressed as percentage of levels
obtained with nonpreincubated recombinant human prorenin.
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we observed that coincubation of recombinant human prore-
nin with 30% plasma at 4°C decreased recombinant human
prorenin binding to myocytes by ’50%. This effect disap-
peared after heat inactivation of soluble plasma M6P/IGFII
receptors. Similar data were obtained with amniotic fluid and
plasma of anephric subjects, thereby indicating that the
absence of prorenin binding during incubation with these
fluids is not due to the presence of exceptionally high soluble
M6P/IGFII receptors in anephric plasma or amniotic fluid. In
fact, the levels of soluble M6P/IGFII receptors in amniotic
fluid are lower than in plasma.22 No data are currently
available on the presence of these receptors in follicular fluid.
The function of soluble M6P/IGFII receptors is not yet
known but may involve transport of IGFII.22 Interestingly, the
levels of soluble M6P/IGFII receptors are highest in circulat-
ing blood plasma of pregnant women and diabetics, two
groups of subjects with high plasma prorenin levels.23,28
Finally, several growth factors in plasma, including insulin
and IGFII, decrease the rate of M6P/IGFII receptor internal-
ization through induction of receptor dephosphorylation,
thereby increasing the steady-state cell-surface M6P/IGFII
receptor number.11 Indeed, preincubation of myocytes with
plasma at 37°C enhanced binding of recombinant human
prorenin by the cells during subsequent incubation at 4°C.
The increase in cell-surface receptor number occurred rapidly
and appeared to diminish on longer incubation with plasma.
Coincubation of cells with recombinant human prorenin
and heat-inactivated plasma at 37°C also resulted in higher
levels of cell-associated prorenin than incubation with recom-
binant human prorenin alone. This confirms that heat inacti-
vation at 56°C does not result in the destruction of growth
factors. Enhanced prorenin binding was not observed when
coincubating noninactivated plasma with recombinant human
prorenin, demonstrating that the growth factor–induced up-
regulation of cell-surface M6P/IGFII receptors may compen-
sate for the decrease in prorenin binding caused by the
presence of soluble M6P/IGFII receptors. Taken together,
therefore, the most likely explanation for the 4- to 10-fold-
lower uptake of plasma and follicular fluid prorenin as
compared with recombinant human prorenin is a difference in
glycosylation and/or phosphorylation between native and
recombinant prorenin.
Conclusions
Myocytes bind and activate native human prorenin through
M6P/IGFII receptors. This process depends on the presence
of the M6P signal on prorenin and is affected by the presence
of soluble M6P/IGFII receptors and growth factors in human
body fluids. These data show the complexity of cardiac
prorenin uptake, which, eventually, determines the degree of
Ang II generation in the heart.
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